Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 1 (2004), Issue 3 (December)

1. Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.
   Gene Ther, 11(24): 1742-52. [Abstract] [Full-text]
2. Mitochondrial injury: a hot spot for parkinsonism and Parkinson's disease?
   Sci Aging Knowledge Environ, 2004(48): pe42. [Abstract] [Full-text]
3. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
   Eur J Neurosci, 20(11): 3121-30. [Abstract] [Full-text]
4. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
   Eur J Nucl Med Mol Imaging, 31(12): 1631-8. [Abstract] [Full-text]
5. Contributions of functional imaging to understanding parkinsonian symptoms.
   Curr Opin Neurobiol, 14(6): 715-9. [Abstract] [Full-text]
6. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
   Behav Brain Res, 156(2): 201-13. [Abstract] [Full-text]
7. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
   Behav Brain Res, 156(2): 191-9. [Abstract] [Full-text]
8. Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease.
   Physiol Behav, 83(3): 395-400. [Abstract] [Full-text]
9. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
   Mol Ther, 11(1): 80-8. [Abstract] [Full-text]
10. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.
    Neurobiol Aging, 26(1): 25-35. [Abstract] [Full-text]
11. Proteome analysis of human substantia nigra in Parkinson's disease.
    Proteomics, 4(12): 3943-52. [Abstract] [Full-text]
12. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease.
    J Zhejiang Univ Sci B, 6(1): 22-7. [Abstract] [Full-text]
13. Fracture rates in Parkinson's disease compared with age- and gender-matched controls: a retrospective cohort study.
    Age Ageing, 34(1): 21-4. [Abstract] [Full-text]
14. Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease.
    J Med Genet, 41(12): 900-7. [Abstract] [Full-text]
15. Rivastigmine for dementia associated with Parkinson's disease.
    N Engl J Med, 351(24): 2509-18. [Abstract] [Full-text]
16. Levodopa and the progression of Parkinson's disease.
    N Engl J Med, 351(24): 2498-508. [Abstract] [Full-text]
17. MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson's disease.
    Exp Neurol, 191(1): 104-18. [Abstract] [Full-text]
18. Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment.
    J Control Release, 101(1): 199-208. [Abstract] [Full-text]
19. By carrot or by stick: cognitive reinforcement learning in parkinsonism.
    Science, 306(5703): 1940-3. [Abstract] [Full-text]
20. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
    Arch Neurol, 61(12): 1920-5. [Abstract] [Full-text]
21. The rate of cognitive decline in Parkinson disease.
    Arch Neurol, 61(12): 1906-11. [Abstract] [Full-text]
22. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease.
    Arch Neurol, 61(12): 1898-904. [Abstract] [Full-text]
23. Mitochondrial ND5 mutations in idiopathic Parkinson's disease.
    Biochem Biophys Res Commun, 326(3): 667-9. [Abstract] [Full-text]
24. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Acta Neurol Scand, 111(1): 21-8. [Abstract] [Full-text]
25. Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease?
    Acta Neurol Scand, 111(1): 12-20. [Abstract] [Full-text]
26. Prevalence of Parkinson's disease in Sydney.
    Acta Neurol Scand, 111(1): 7-11. [Abstract] [Full-text]
27. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.
    Brain, 128: 126-37. [Abstract] [Full-text]
28. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
    Proc Natl Acad Sci U S A, 101(50): 17510-5. [Abstract] [Full-text]
29. Visually guided movements suppress subthalamic oscillations in Parkinson's disease patients.
    J Neurosci, 24(50): 11302-6. [Abstract] [Full-text]
30. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration.
    Neuron, 44(6): 931-45. [Abstract] [Full-text]
31. Deep brain stimulation for Parkinson's disease: association between stimulation parameters and cognitive performance.
    Stereotact Funct Neurosurg, 82(4): 191-3. [Abstract] [Full-text]
32. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress.
    Hum Mol Genet, 14(1): 71-84. [Abstract] [Full-text]
33. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases.
    J Neurol Neurosurg Psychiatry, 76(1): 115-7. [Abstract] [Full-text]
34. Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson's disease dementia and Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 76(1): 106-8. [Abstract] [Full-text]
35. Taste responses in patients with Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 76(1): 40-6. [Abstract] [Full-text]
36. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias?
    J Neurol Neurosurg Psychiatry, 76(1): 34-9. [Abstract] [Full-text]
37. Sleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: a polysomnographic study.
    J Neurol Sci, 228(1): 7-10. [Abstract] [Full-text]
38. Pathogenic mutations inactivate parkin by distinct mechanisms.
    J Neurochem, 92(1): 114-22. [Abstract] [Full-text]
39. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy.
    Eur J Neurol, 12(1): 9-15. [Abstract] [Full-text]
40. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
    Eur J Neurol, 12(1): 1-8. [Abstract] [Full-text]
41. Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
    Neurosci Lett, 373(3): 189-94. [Abstract] [Full-text]
42. Parkinsonism associated with neurocysticercosis.
    Parkinsonism Relat Disord, 11(1): 69-72. [Abstract] [Full-text]
43. Micrographia on free writing versus copying tasks in idiopathic Parkinson's disease.
    Parkinsonism Relat Disord, 11(1): 57-63. [Abstract] [Full-text]
44. The Parkinson fatigue scale.
    Parkinsonism Relat Disord, 11(1): 49-55. [Abstract] [Full-text]
45. S100B and NSE serum levels in patients with Parkinson's disease.
    Parkinsonism Relat Disord, 11(1): 39-43. [Abstract] [Full-text]
46. Body mass index is reduced early in Parkinson's disease.
    Parkinsonism Relat Disord, 11(1): 35-8. [Abstract] [Full-text]
47. Temporal variability of gait in Parkinson disease: effects of a rehabilitation programme based on rhythmic sound cues.
    Parkinsonism Relat Disord, 11(1): 25-33. [Abstract] [Full-text]
48. Measuring gait and gait-related activities in Parkinson's patients own home environment: a reliability, responsiveness and feasibility study.
    Parkinsonism Relat Disord, 11(1): 19-24. [Abstract] [Full-text]
49. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.
    Proc Natl Acad Sci U S A, 101(52): 18171-6. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.